Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Next Previous
Trial Profile

A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meropenem/vaborbactam (Primary) ; Antibacterials
  • Indications Bacteraemia; Enterobacteriaceae infections; Intra-abdominal infections; Pyelonephritis; Urinary tract infections; Ventilator associated pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO 2; TANGO II
  • Sponsors Rempex Pharmaceuticals; The Medicines Company

Most Recent Events

  • 07 Jun 2021 Results of a population pharmacokinetic analysis using pooled data from two Phase 1 (Rempex501 & Rempex504) and two Phase 3 studies ( TANGO 1 & TANGO 2) published in the Antimicrobial Agents and Chemotherapy
  • 19 Nov 2020 Results evaluating cost-effectiveness of Vaborem in the Italian setting, by taking data efficacay data from TANGO II, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 16 May 2019 Results of Post Hoc analysis assessing the efficacy of MV versus best available therapy in the subgroup of patients without prior antimicrobial failure published in the Advances in Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top